TRVI Stock Price, Chart, Stats & News
Trevi Therapeutics, Inc. (TRVI) does not currently pay a dividend.
TRVI chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.15% |
ROA | -22.10% |
ROE | -25.49% |
D/E | 0.00x |
Interest coverage ratio | – |
TRVI valuation
P/E | – |
P/S | – |
P/B | 9.00x |
P/CF | -39.17x |
P/FCF | -50.82x |
P/OCF | -39.17x |
PEG | -2.85x |
EV multiple | -33.05x |
About
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations.
Similar securities
Based on sector and market capitalization
